An Inactivated Virus Candidate Vaccine to Prevent COVID-19

Side Effects of First and Second Doses of Inactivated COVID-19 Vaccine in Multiple Sclerosis

Background: It is currently recommended to vaccinate against SARS CoV-2 for people with multiple sclerosis (MS), but it is uncertain what effect it will have on people with MS (PwMS). Objectives: We aimed to compare the side effects of the first and second doses of the Sinopharm vaccine in PwMS. Materials & Methods: This descriptive-analytical follow-up study was conducted on PwMS patients...

Inactivated African Horse Sickness Virus Cell Culture Vaccine

Strategies of vaccine production against COVID-19: when will an effective vaccine be produced?

There is a strong consensus globally that production of an effective vaccine against SARS-CoV-2 is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. In this paper, we review vaccine candidate against COVID-19 and also cha...

Ethical Issues in COVID-19 Vaccine Rollout

From the beginning of the COVID-19 pandemic, researchers aspired to produce an effective vaccine with appropriate efficacy and low side effects to mitigate the pandemic. It seems that vaccination is the only mean to save the world from this pandemic. In this article, we will review the ethical challenges of mass vaccination (focusing on the vaccine distribution and uptake), referring to the mai...

Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.

We evaluated a novel psoralen-inactivated dengue virus type 1 (DENV-1) vaccine candidate in Mus musculus mice. Mice received intradermal alum or 5 to 10 ng of psoralen-inactivated virus. Anti-DENV-1 neutralizing antibody was detectable in 10/11 mice receiving a 10-ng dose at 90 days. Psoralen-inactivated DENV-1 is immunogenic in mice.